2020 Fourth Quarter Business Review and 2021 Outlook (Unaudited) January 26, 2021 -- 1 of 22 -- 2 2020 Q1 Earnings – April 28, 2020. All rights reserved. Events 2021 Earnings Calls Q1 April 27, 2021 Q2 July 27, 2021 Q3 October 26, 2021 -- 2 of 22 -- 3 2020 Q4 Earnings – January 26, 2021. All rights reserved. Forward looking statement This presentation contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as "anticipate," "estimate," "expect," "aim," "project," "intend," "plan," "believe," "will," "should," "could," "target," "forecast" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19); (3) liabilities related to certain fluorochemicals, including lawsuits concerning various PFAS-related products and chemistries, and claims and governmental regulatory proceedings and inquiries related to PFAS in a variety of jurisdictions; (4) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2019, and any subsequent quarterly reports on Form 10-Q (the “Reports”); (5) competitive conditions and customer preferences; (6) foreign currency exchange rates and fluctuations in those rates; (7) the timing and market acceptance of new product offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (11) operational execution, including scenarios where the Company generates fewer productivity improvements than estimated; (12) financial market risks that may affect the Company’s funding obligations under defined benefit pension and postretirement plans; and (13) the Company's credit ratings and its cost of capital. Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under "Cautionary Note Concerning Factors That May Affect Future Results" and "Risk Factors" in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports), as updated by applicable Current Reports on Form 8-K. The information contained in this presentation is as of the date indicated. The Company assumes no obligation to update any forward-looking statements contained in this presentation as a result of new information or future events or developments. This presentation refers to certain non-GAAP financial measures. Refer to 3M’s January 26, 2021 press release for descriptions of non-GAAP financial measures such as adjusted free cash flow, adjusted free cash flow conversion, return on invested capital (ROIC), net debt, adjusted EBITDA, and various measures that adjust for the impacts of special items. These non-GAAP measures are not in accordance with, nor are they a substitute for, GAAP measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in that press release. Note on non-GAAP financial measures -- 3 of 22 -- 4 2020 Q4 Earnings – January 26, 2021. All rights reserved. • Continuing to fight the COVID-19 pandemic from every angle • Strong Q4: broad-based growth, improved margins, robust cash flow • 2020: executed well while transforming for the future • Accelerating investments in growth, productivity, and sustainability • Initiating full-year 2021 guidance; well positioned for growth Protecting employees, serving customers and delivering for shareholders 3M is delivering and well positioned for the future -- 4 of 22 -- 5 2020 Q4 Earnings – January 26, 2021. All rights reserved. Q4 2020 performance: strong finish to the year Sales of $8.6B, up 5.8% year-on-year • Organic growth across all business segments and geographic areas • COVID-related respirator sales growth of ~$280M, or +3.5 ppts contribution to total company sales growth End-market trends year-on-year • Strength: personal safety, home improvement, semiconductor, data center, home cleaning and biopharma filtration • Weakness: hospitality, healthcare and oral care elective procedures, healthcare IT and office supplies Adjusted EBITDA margins of 27.3%, up 260 bps year-on-year Adjusted free cash flow of $2.1B, up 16% year-on-year Reduced net debt by $1.3B, or 9% sequentially 5.5% year-on-year Organic local- currency growth $2.38 +22.1% year-on-year Adjusted earnings per share 21.5% +2.5 ppts year-on- year Adjusted operating margin -- 5 of 22 -- 6 2020 Q4 Earnings – January 26, 2021. All rights reserved. Q4 2020 P&L $8.6B +5.8% year-on-year Net sales $1.8B +20.1% year-on-year Adjusted operating income $1.4B +22.4% year-on-year Adjusted net income Q4 2019 19.0% Organic volume/ productivity and other +1.6% Organic volume growth; disciplined cost management/productivity; Q4 2020 gain on sale of properties (+0.6%); increase in respirator mask reserve (-0.9%) Acquisitions/divestitures +0.1% Primarily drug delivery divestiture Price/raw material +0.8% Selling prices up 0.8% year-on-year; lower raw material costs FX -0.1% Net of hedge impact Restructuring +0.1% Pre-tax charge Q4 2020 $137M vs. Q4 2019 $134M Q4 2020 21.5% Adjusted operating income margin reconciliation: -- 6 of 22 -- 7 2020 Q4 Earnings – January 26, 2021. All rights reserved. Adjusted earnings per share reconciliation: Q4 2019 $1.95 Organic growth/ productivity and other +$0.43 Organic sales growth; disciplined cost management/productivity; Q4 2020 gain on sale of properties (+$0.09); increase in respirator mask reserve (-$0.10) Acquisitions/divestitures -$0.02 Primarily drug delivery divestiture FX +$0.02 Pre-tax earnings impact of +$13M Restructuring $0.00 Pre-tax charge Q4 2020 $137M vs. Q4 2019 $134M Other expense/shares outstanding -$0.03 Primarily higher net interest (including early debt retirement) Tax rate* +$0.03 Underlying tax rate; rate benefited by geographic mix of pre-tax income Q4 2020 $2.38 Q4 2020 adjusted EPS +9.0% $2.38 +22.1% year-on-year Adjusted earnings per share * The effect of income taxes on items that had specific tax rates are reflected within their respective impacts in the table above. -- 7 of 22 -- 8 2020 Q4 Earnings – January 26, 2021. All rights reserved. Q4 2020 cash flow and balance sheet Adjusted free cash flow of $2.1B, up 16% year-on-year • FY 2020: $6.7B, up 18% year-on-year Adjusted free cash flow conversion of 151% • FY 2020: 132%, up 22 ppts vs. last year Capital expenditures: • Q4 2020: $422M, down $116M year-on-year • FY 2020: $1.5B, down $198M year-on-year Net debt: • Q4 2020 $13.7B vs. Q3 2020 $15.0B, down 9% • YE 2020 $13.7B vs. YE 2019 $17.8B, down 23% Cash returned to shareholders • FY 2020: $3.8B in cash dividends paid and share repurchases $2.1B Adjusted free cash flow $5.1B Cash & marketable securities $0.8B Dividends -- 8 of 22 -- 9 2020 Q4 Earnings – January 26, 2021. All rights reserved. Q4 Business Group performance Sales Organic growth Segment Operating Margin Change Commentary Change Safety & Industrial $3.1B +11.4% 27.7% +6.9 ppts • Organic sales grew in personal safety, roofing granules, industrial adhesives and tapes, and electrical markets; declined automotive aftermarket, abrasives, and closure and masking systems • Organic sales growth benefited by 9.9 ppts due to pandemic related respirator mask demand • Segment operating margin improvement driven by sales growth, strong productivity, continued spending discipline and property sale gain Transportation & Electronics $2.3B +1.4% 21.8% +1.0 ppts • Organic sales grew in automotive and aerospace, transportation safety, electronics, and advanced materials; declined in commercial solutions • Segment operating margin improvement driven by continued spending discipline Health Care $2.3B +6.6% 24.7% +3.4 ppts • Organic sales grew in medical solutions, separation and purification, and food safety; declined in oral care and health information systems • Segment operating margin improvement driven by continued spending discipline, partially offset by higher restructuring costs Consumer $1.4B +9.9% 23.5% Flat • Organic sales grew in home improvement, home care, and consumer healthcare; declined in stationery and office supplies • Segment operating margins improvement driven by sales growth and strong productivity, offset by increased investments in ad merch, new product innovation, and higher restructuring costs -- 9 of 22 -- 10 2020 Q4 Earnings – January 26, 2021. All rights reserved. 2020 full-year performance -1.7% Organic local currency growth $8.74 Adjusted earnings per share 18.2% Return on invested capital 132% Adjusted free cash flow conversion • Delivered for our customers and generated adjusted free cash flow of $6.7 billion • Expanded adjusted EBITDA margins to 27.2%, up 100 basis points year-on-year • Strength and resiliency of operating model and disciplined capital allocation enabled $4.1 billion reduction in net debt • Strengthened Health Care portfolio; executed integration of Acelity and completed drug delivery divestiture • Returned $3.8 billion to shareholders via cash dividends and share repurchase • 2020 marked the 62nd consecutive year of increase in annual dividend Executed well and delivered strong cash flow -- 10 of 22 -- 11 2020 Q4 Earnings – January 26, 2021. All rights reserved. Delivering today, building for a stronger tomorrow Fought the pandemic from every angle • Produced and delivered 2 billion respirators; expanded production capacity to 2.5 billion units • Helped speed vaccine and therapeutic development • Partnered with governments to maintain PPE supply Executed for customers and end markets where demand was strong • Personal safety; home improvement; semiconductor; data centers; general cleaning; biopharma filtration Advanced business model and invested in efficiency, productivity, and growth • Increased pace of innovation; expanded partnerships • Delivered strong supply chain execution despite macroeconomic disruption and uncertainty • Initiated restructuring actions to reduce annual operating costs by $250 million to $300 million -- 11 of 22 -- 12 2020 Q4 Earnings – January 26, 2021. All rights reserved. Positioned for strong 2021 performance Accelerating investments in growth, productivity and sustainability • Forecasting organic sales growth of 3 to 6 percent, improvement in margins and earnings, and strong cash flow generation • Prioritizing investments in end markets where demand is strong and sustainable … personal safety, health care, auto OEM, semiconductor, data center, and home improvement … and Priority Growth Platforms • Optimizing business group-led global operating model, business processes, and streamlining global organization • Accelerating pace of manufacturing technology deployment • Advancing operating rigor through end-to-end digitization and leveraging data and data analytics • Stepping up ESG leadership: enhancing sustainability including air and water stewardship; advancing diversity, equity and inclusion -- 12 of 22 -- 13 2020 Q4 Earnings – January 26, 2021. All rights reserved. Full-year 2021 planning estimates Sales growth of 5% to 8%: • Organic local-currency: 3% to 6% • Divestitures: approx. -0.5% • Foreign currency translation: approx. 2% Disciplined capital allocation: • Cap-ex: $1.8B to $2.0B • Pension contributions: $0.1B to $0.2B • Restarting share repurchase program Continue to strengthen capital structure and financial flexibility 3% to 6% Organic local currency growth $9.20 to $9.70 Earnings per share 95% to 105% Free cash flow conversion -- 13 of 22 -- 14 2020 Q4 Earnings – January 26, 2021. All rights reserved. 2021 organic local-currency growth segment expectations Business Groups Organic Growth Macroeconomic/End-Market Factors Safety & Industrial Mid-single digits • Pace and success of vaccine deployment and adoption • 2021 global GDP and IPI expected up mid-single digits • Semiconductor; data center; consumer electronic device demand • Car & light truck builds • Disposable respirator demand • Return-to-workplace/return-to-school trends • Healthcare and oral care elective procedure volumes • Retail sales and e-commerce strength • Home improvement trends Transportation & Electronics Low to high- single digits Health Care Low to mid- single digits Consumer Low to mid- single digits Total 3M: 3% to 6% -- 14 of 22 -- 15 2020 Q1 Earnings – April 28, 2020. All rights reserved. Q&A Mike Roman Chairman and Chief Executive Officer Monish Patolawala Senior Vice President and Chief Financial Officer Bruce Jermeland Vice President, Investor Relations -- 15 of 22 -- 16 2020 Q4 Earnings – January 26, 2021. All rights reserved. Appendix -- 16 of 22 -- 17 2020 Q4 Earnings – January 26, 2021. All rights reserved. Q4 2020 P&L ($M) Q4 2019 Q4 2020 Change Sales $8,111 $8,583 +5.8% Gross profit $3,786 $4,195 +10.8% % to sales 46.6% 48.8% +2.2 pts SG&A $1,940 $1,890 -2.6% % to sales 23.9% 22.0% -1.9 pts R&D & related $521 $456 -12.4% % to sales 6.4% 5.3% -1.1 pts Operating income $1,325 $1,849 +39.5% % to sales 16.3% 21.5% +5.2 pts Net income $969 $1,389 +43.4% GAAP earnings per share $1.66 $2.38 +43.4% -- 17 of 22 -- 18 2020 Q4 Earnings – January 26, 2021. All rights reserved. Q4 2020 sales recap Americas EMEA Asia Pacific Organic volume +6.6% +3.8% +2.1% Price +1.3% +1.8% -0.4% Organic local-currency +7.9% +5.6% +1.7% Acquisitions/Divestitures -0.9% -3.2% -0.2% FX -1.2% +5.0% +3.8% Total growth +5.8% +7.4% +5.3% U.S. Canada Mexico Brazil China Japan Organic local-currency +9% +2% Flat +21% +14% -4% -- 18 of 22 -- 19 2020 Q4 Earnings – January 26, 2021. All rights reserved. Business segment information ($M) Net Sales Q4 2020 Sales Growth Organic local-currency by Geographic Area Business Segment Operating Income/Adjusted Operating Income* Business Segment Operating Margin /Adjusted Operating Margin* Business groups Q4 2019 Q4 2020 Organic local- currency FX M&A Total Sales change Americas Asia Pacific EMEA Q4 2019 Q4 2020 Percent Change Q4 2019 Q4 2020 Safety & Industrial $2,785 $3,140 11.4% 1.3% 0.0% 12.7% 15% 2% 14% $579 $869 49.9% 20.8% 27.7% Transportation & Electronics $2,286 $2,338 1.4% 2.2% -1.3% 2.3% -1% 3% Flat $474 $511 7.5% 20.8% 21.8% Health Care $2,141 $2,257 6.6% 1.6% -2.8% 5.4% 9% flat 7% $457 $558 22.3% 21.3% 24.7% Consumer $1,289 $1,425 9.9% 0.7% 0.0% 10.6% 13% -2% 9% $303 $335 10.7% 23.5% 23.5% Elimination of Dual Credit ($402) ($577) ($101) ($150) Total Operating Business Segment $1,712 $2,123 Corporate and Unallocated $12 --- ($173) ($274) Total $8,111 $8,583 5.5% 1.4% -1.1% 5.8% 7.9% 1.7% 5.6% $1,539 $1,849 20.1% 19.0% 21.5% Organic local-currency = organic volume + price * “Corporate and Unallocated” and “Total” provided on an adjusted basis -- 19 of 22 -- 20 2020 Q4 Earnings – January 26, 2021. All rights reserved. Sales by division ($M) Net Sales Business groups Q4 2019 Q4 2020 Abrasives 328 317 Automotive Aftermarket 312 306 Closure and Masking Systems 276 248 Electrical Materials 288 292 Industrial Adhesives and Tapes 648 689 Personal Safety 851 1,212 Roofing Granules 73 95 Other Safety & Industrial 9 (19) Total Safety & Industrial Business Group 2,785 3,140 Advanced Materials 284 266 Automotive & Aerospace Solutions 450 487 Commercial Solutions 403 382 Electronics 951 996 Transportation Safety 202 212 Other Transportation & Electronics (4) (5) Total Transportation & Electronics Business Group 2,286 2,338 ($M) Net Sales Business groups Q4 2019 Q4 2020 Drug Delivery 95 - Food Safety 87 90 Health Information Systems 324 307 Medical Solutions 1,120 1,315 Oral Care 330 335 Separation & Purification 189 214 Other Health Care (4) (4) Total Health Care Business Group 2,141 2,257 Consumer Health Care 84 88 Home Care 244 270 Home Improvement 568 664 Stationery and Office 370 364 Other Consumer 23 39 Total Consumer Business Group 1,289 1,425 Corporate and Unallocated 12 - Elimination of Dual Credit (402) (577) Total 8,111 8,583 -- 20 of 22 -- 21 2020 Q4 Earnings – January 26, 2021. All rights reserved. 0.40 to 0.70 (0.05) 0.15 (0.10) to neutral (0.35) to (0.45) 0.20 to 0.35 0.20 to 0.30 Neutral Growth and Portfolio Management Raw Materials & Productivity Other Financial $8.74 2021 EPS roadmap $9.20 to $9.70 -- 21 of 22 -- -- 22 of 22 --